<bill session="114" type="h" number="5414" updated="2017-06-02T22:03:57Z">
  <state datetime="2016-06-08">REFERRED</state>
  <status>
    <introduced datetime="2016-06-08"/>
  </status>
  <introduced datetime="2016-06-08"/>
  <titles>
    <title type="short" as="introduced">FDA Cross-Center Collaboration Act of 2016</title>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act to provide for establishment of one or more Intercenter Institutes within the Food and Drug Administration for a major disease area or areas, and for other purposes.</title>
    <title type="display">FDA Cross-Center Collaboration Act of 2016</title>
  </titles>
  <sponsor id="400414"/>
  <cosponsors>
    <cosponsor id="400308" joined="2016-06-08"/>
  </cosponsors>
  <actions>
    <action datetime="2016-06-08">
      <text>Introduced in House</text>
    </action>
    <action datetime="2016-06-08" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill relation="unknown" session="114" type="s" number="2700"/>
    <bill relation="unknown" session="114" type="h" number="34"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Executive agency funding and structure"/>
    <term name="Food and Drug Administration (FDA)"/>
    <term name="Government employee pay, benefits, personnel management"/>
    <term name="Health promotion and preventive care"/>
    <term name="Medical education"/>
  </subjects>
  <amendments/>
  <summary date="2016-06-08T04:00:00Z" status="Introduced in House">FDA Cross-Center Collaboration Act of 2016

This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to establish one or more Intercenter Institutes. Each institute must coordinate activities applicable to a major disease area among the FDA centers that review products. Activities may include coordinating staff with relevant expertise, streamlining product review, and enhancing interactions with patients, sponsors, and the biomedical community.</summary>
  <committee-reports/>
</bill>
